Lifecore Biomedical, Inc. (LFCR)
NASDAQ:LFCR
Want to see LFCR full AI Analyst Report?
Top Page
Lifecore Biomedical
(NASDAQ:LFCR)
Select Model
Select Model
Rating:42Neutral
Price Target:
$4.50
▼(-41.63% Downside)
Action:Reiterated
Date:05/09/26
LFCR scores low primarily due to weak financial fundamentals (revenue decline, persistent net losses, and high leverage despite improved cash flow). Technicals add pressure with the stock trading below major moving averages and negative MACD. Valuation is also impaired because the company is loss-making (negative P/E) and no dividend yield is available to offset risk.
Positive Factors
CDMO end-to-end services
A focused CDMO model for sterile injectables with end-to-end capabilities creates durable customer stickiness. Specialized aseptic fill-and-finish and analytical services are high technical-barrier offerings that support recurring development and commercial contracts and long-term revenue visibility.
Negative Factors
High leverage
Very high debt relative to equity materially constrains financial flexibility and raises refinancing risk. Persistent leverage increases interest burden and limits the company's ability to invest in capacity or absorb demand shocks, making long-term growth execution riskier.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO end-to-end services
A focused CDMO model for sterile injectables with end-to-end capabilities creates durable customer stickiness. Specialized aseptic fill-and-finish and analytical services are high technical-barrier offerings that support recurring development and commercial contracts and long-term revenue visibility.
Read all positive factors
Lifecore Biomedical (LFCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$186.80M
Dividend YieldN/A
Average Volume (3M)258.94K
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue Growth0.47%
EPS Growth-430.88%
CountryUS
Employees524
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.03
Shares Outstanding37,509,407
10 Day Avg. Volume206,497
30 Day Avg. Volume258,940
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)175.14
Price to Sales (P/S)1.82
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.68
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit7.46
Enterprise Value/Ebitda115.24
Forecast
1Y Price Target
$6.67Price Target Upside-13.53% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.02
Revenue Forecast (FY)$122.23M
Lifecore Biomedical Business Overview & Revenue Model
Company Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. Th...
How the Company Makes Money
Lifecore primarily makes money by providing outsourced development and manufacturing services to biopharmaceutical and medical product companies. Its core revenue stream is service revenue tied to (1) CDMO development work (e.g., formulation and p...
Lifecore Biomedical Earnings Call Summary
Earnings Call Date:Mar 16, 2026
(Q5-2025)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call conveys a generally positive tone: strong revenue growth (+26%), a meaningful adjusted EBITDA turnaround (to $3.1M), substantial SG&A reductions (~$5.9M), and multiple commercial and pipeline milestones (new wins, quality audits, automation/validation progress). Offsetting these positives are continued GAAP losses ($10M), a decline in CDMO gross profit driven by product mix and lower development revenue, reliance on a large customer's 2027 inflection and multi-year timelines for commercial site transfers, and remaining work to reach the company's 25% adjusted EBITDA margin target. On balance the operational progress, improved profitability on an adjusted basis, and new business momentum outweigh the near-term challenges and timing risks.Positive Updates
Strong Revenue Growth
Revenue for the 3 months ended Sept 30, 2025 was $31.1M, a 26% increase versus $24.7M in the comparable prior period. The increase was driven primarily by a $4.8M rise in HA manufacturing revenues and $1.6M increase in CDMO revenues (higher sales volumes of $2.6M partially offset by lower development revenue).
Negative Updates
Continued Net Loss
Reported net loss of $10.0M (loss per diluted share $0.29) for the quarter, improved from $16.2M ($0.53) but the company remains unprofitable on a GAAP basis.
Read all updates
Q5-2025 Updates
Positive
Negative
Strong Revenue Growth
Revenue for the 3 months ended Sept 30, 2025 was $31.1M, a 26% increase versus $24.7M in the comparable prior period. The increase was driven primarily by a $4.8M rise in HA manufacturing revenues and $1.6M increase in CDMO revenues (higher sales volumes of $2.6M partially offset by lower development revenue).
Read all positive updates
Company Guidance
Management reaffirmed transition-period guidance for May 26–Dec 31, 2025 of revenue $74–$76M, net loss of $18.4–$16.4M and adjusted EBITDA of $12–$14M; they also outlined remaining-Q4 guidance of $34–$36M (≈$35M midpoint, ~8% y/y) after estimated June revenue of $8.7M (CDMO $6.6M; HA $2.1M) and YTD (through Sept 30) stub revenue of ≈$39.8M. June adjusted EBITDA was ≈$1.5M, leaving YTD adj. EBITDA ≈$4.6M and implied Q4 adj. EBITDA guidance of $7–$9M (≈$8M midpoint), which produces an implied stub-period adjusted EBITDA margin of roughly 17% at the midpoint (vs. Q3’s ~10%: $3.1M adj. EBITDA on $31.1M revenue); management continues to target a midterm adjusted EBITDA margin of 25% and expects calendar‑2026 revenue to be weighted ~45% H1 / ~55% H2.Lifecore Biomedical Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
56
Neutral
| Breakdown | TTM | May 2025 | May 2024 | Aug 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 135.16M | 128.87M | 128.26M | 103.27M | 111.27M | 100.87M |
| Gross Profit | 42.13M | 40.30M | 41.85M | 27.98M | 39.07M | 38.94M |
| EBITDA | 2.73M | -8.81M | 35.60M | -33.17M | 12.84M | -987.00K |
| Net Income | -34.09M | -38.72M | 12.01M | -99.56M | -116.72M | -32.29M |
Balance Sheet | ||||||
| Total Assets | 225.50M | 239.34M | 253.96M | 253.54M | 274.70M | 502.92M |
| Cash, Cash Equivalents and Short-Term Investments | 20.80M | 8.27M | 8.46M | 19.09M | 991.00K | 1.16M |
| Total Debt | 150.14M | 130.82M | 133.57M | 112.62M | 247.78M | 215.86M |
| Total Liabilities | 204.72M | 238.01M | 242.65M | 257.77M | 186.88M | 300.14M |
| Stockholders Equity | 20.78M | 1.34M | 11.31M | -4.23M | 87.82M | 202.78M |
Cash Flow | ||||||
| Free Cash Flow | 10.47M | -13.62M | -18.14M | -38.92M | -52.53M | -8.75M |
| Operating Cash Flow | 17.38M | -206.00K | 257.00K | -17.44M | -22.59M | 16.47M |
| Investing Cash Flow | 3.09M | -6.42M | -18.39M | -4.81M | 79.96M | -12.31M |
| Financing Cash Flow | -5.09M | 6.42M | 7.51M | 39.70M | -57.02M | -3.42M |
Lifecore Biomedical Technical Analysis
Neutral
7.71
Price Trends
4.64
Positive
6.15
Negative
6.78
Negative
Market Momentum
-0.09
Negative
53.66
Neutral
76.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Neutral. The current price of 7.71 is above the 20-day moving average (MA) of 4.80, above the 50-day MA of 4.64, and above the 200-day MA of 6.78, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 53.66 is Neutral, neither overbought nor oversold. The STOCH value of 76.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LFCR.
Lifecore Biomedical Risk Analysis
Lifecore Biomedical disclosed 30 risk factors in its most recent earnings report. Lifecore Biomedical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lifecore Biomedical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $633.76M | 3.52 | -38.88% | ― | 13.80% | ― | |
57 Neutral | $82.56M | -3.87 | -28.75% | ― | 2.08% | -106.57% | |
53 Neutral | $170.99M | -14.36 | -35.57% | ― | 15.00% | 3.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $744.14M | -8.35 | -29.40% | ― | 610.96% | -18.43% | |
42 Neutral | $186.80M | -2.33 | -146.68% | ― | 0.47% | -430.88% |
* Healthcare Sector Average
LFCR
Lifecore Biomedical
4.93
-1.79
-26.64%
IRWD
Ironwood Pharma
3.92
3.35
592.58%
CPIX
Cumberland Pharmaceuticals
5.87
0.53
9.93%
SXTC
China SXT Pharmaceuticals
1.66
-230.84
-99.29%
DERM
Journey Medical Corp
5.96
-1.81
-23.29%
BIOA
BioAge Labs, Inc.
16.61
12.66
320.51%
Lifecore Biomedical Corporate Events
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Lifecore Sets 2026 Annual Meeting, Proposal Deadlines
Neutral
Mar 5, 2026
On August 1, 2025, Lifecore Biomedical’s board approved a shift in its fiscal year from one ending on the last Sunday in May to a calendar-year basis ending December 31, effective for the fiscal period from May 26, 2025 to December 31, 2025,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.